BioScience Slovakia is a unique biotechnology company focused on development of innovative diagnostics and treatment tools in the area of cancer and virology. Our mission is to transform the extensive research potential and intellectual property accumulated in local research institutions into highly valuable practical outcomes, both from the medical and commercial point of view. Cancer diagnostics The product development in the area of cancer diagnostics is primarily based around MN protein (carbonic anhydrase IX protein or CA IX). This protein can be used as a prognostic and/or predictive marker, as it is typical for aggressive, solid tumors that are often resistant to conventional treatment. Our ELISA kit is entering clinical validation phase. Cancer treatment Using antibodies to CA IX, which represents excellent target for anticancer therapy due to its selective expression on hypoxic solid tumors, the company has developed a humanised monoclonal antibody that shows internalisation properties and excellent biological activity in pre-clinical evaluations. This antibody could be used for CA IX targeted immunotherapy. Virus diagnostics Is focused on the diagnostics of the lymphocytic choriomeningitis virus (LCMV), a rodent-borne virus causing zoonotic infections in humans, which are mostly asymptomatic, but can cause significant health complications with occasional fatal outcome in persons with compromised or suppressed immunity, such as patients undergoing organ transplantation, chemotherapy and pregnant women.